U.S. Markets open in 5 hrs 27 mins

Opioid Alternatives Could Make Investors Major Gains

HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs are also looking like interesting opportunities after seeing some selling in recent weeks. There are a couple stocks we are highlighting for each sector to pay attention to this week.

We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA), Arena Pharmaceuticals, Inc. (ARNA), and Axim Technologies, Inc. (AXIM).

One of the largest problems both biotech and CBD industries are working to combat is the opioid crisis. One of the biggest issues in developing new therapies to replace opioids has been creating options without adverse side effects while also providing effective pain relief.

There is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies Endonovo Therapeutics, Inc.(ENDV) (Market Cap: $21.77M Share Price: $0.0335) that may solve this lconundrum. ENDV has developed a therapy that could help lessen the pain without the kinds of side effects many other options have. Their non-invasive easy to use ORTHOHALO™ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation. There are no known side effects and no potential for overdose or dependency.

This is one of the most intriguing opioid alternative we've found because it can be used for several pain inducing conditions, many of the other companies we've found are a bit more specific.

One company that is focused on treating fibromyalgia and peripheral neuropathic pain is Zynerba Pharmaceuticals (ZYNE) (Market Cap: $93.24M Share Price: $5.29). ZYNE is an entirely clinical-stage drug developer with two drugs in its pipeline. ZYN001, which is a tetrahydrocannabinol (THC) pro-drug patch, is aimed at treating fibromyalgia and peripheral neuropathic pain. It's also a drug that's only now moving into early stage studies. The allure of ZYN001, if it works, is that it's absorbed directly through the skin, thus avoiding first-pass liver metabolism, potentially even requiring a lower dose to achieve the desired efficacy of pain relief.

Cara Therapeutics (CARA) (Market Cap: $751.06M Share Price: $19.04) has conducted preclinical rodent models, their CR701 wound up reducing hyperalgesia (sensitization of nerve ending to painful stimuli) and allodynia (painful perception of innocuous stimuli) in a setting considered comparable to human conditions.

Arena Pharmaceuticals, Inc. (ARNA) (Market Cap: $2.05B Share Price: $41.68) well for developing weight-loss drug Belviq, has shown promise with APD371, an oral Crohn's disease pain drug that targets the CB2 receptor. Initial safety and dose finding phase 1b studies found APD371 to be safe. This company is certainly worth radaring.

Clinical-stage cannabinoid-based drug developer Axim Biotechnologies (AXIM) (Market Cap: $66.87M Share Price: $1.13) has more than a dozen indications in its pipeline. Of particular note, the company's chewing gum delivery mechanism, MedChew-1401 for multiple sclerosis/pain spasticity, and CanQuit O, for opioid addiction, may offer hope for a move away from opioid use. Axim's chewing gum contains equal parts THC and cannabidiol, the non-psychoactive component of cannabis.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve month agreement, and can be canceled at anytime by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC